-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2024-514875-16-00
4
2024-10-21
First-line treatment of PD-L1-positive recurrent or metastatic head an
-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2024-514610-13-00
5
2024-10-04
patients suffering from acute myocarditis confirmed on Cardiac magneti
-
2023-504986-22-00
5
2024-09-30
surgical antibiotic prophylaxis
-
2023-503316-33-00
5
2024-09-26
patients with a positive status for molecular residual disease (MRD) [
-
2024-511070-68-01
5
2024-09-24
Ampullary adenocarcinoma
-
2022-500800-24-00
4
2024-09-19
Multiple Myeloma
-
2024-517204-11-00
4
2024-08-30
microsatellite stable (MSS) colorectal cancer with liver-dominant meta
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2024-516272-14-00
5
2024-08-13
renal transplant
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-514083-31-00
4
2024-07-26
squamous cell anal carcinoma
-
2023-509905-62-00
5
2024-07-19
Lower limb trauma requiring immobilisation
-
2022-502135-19-00
4
2024-07-18
Calcific Aortic Valve Stenosis
-
2023-505298-34-00
4
2024-07-18
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
-
2024-514107-34-00
4
2024-07-18
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2022-500013-32-01
5
2024-07-05
Adrenocortical carcinoma
-
2023-508100-38-00
5
2024-06-24
Advanced Biliary Cancer (ABC)
-
2023-504514-29-00
1
2024-06-18
Gastroesophageal Junction (GEJ) Adenocarcinoma